JP4975440B2 - 黄斑変性およびその他の眼科疾患の改善 - Google Patents
黄斑変性およびその他の眼科疾患の改善 Download PDFInfo
- Publication number
- JP4975440B2 JP4975440B2 JP2006541460A JP2006541460A JP4975440B2 JP 4975440 B2 JP4975440 B2 JP 4975440B2 JP 2006541460 A JP2006541460 A JP 2006541460A JP 2006541460 A JP2006541460 A JP 2006541460A JP 4975440 B2 JP4975440 B2 JP 4975440B2
- Authority
- JP
- Japan
- Prior art keywords
- eye
- tempol
- pharmaceutical composition
- composition
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Description
発明の詳細な説明
本発明は、現在の薬理学的治療が少ないかまたは完全に脱落している多数の眼科疾患または障害の処置または防御の方法を提供する。具体的には、黄斑変性、糖尿病網膜症およびその他の網膜症の軽減のための方法を提供し、それには、脈絡膜新生血管膜形成症(CNVM)、黄斑変性、網膜上膜形成症(ERM)(黄斑皺襞症)および黄斑円孔症、ならびに緑内障、ブドウ膜炎、および角膜(および周囲の眼瞼および結膜)の障害を含み、これらに限定はされず、炎症、外傷、放射線損傷、角膜血管新生症および各種のジストロフィー、例えばフックスジストロフィー、円錐角膜、格子状ジストロフィーおよびマップ・ドット・フィンガープリントジストロフィー、ならびに眼乾燥症候群、眼瞼炎および眼の酒さを含み、これらに限定はされない。黄斑変性の進行に関係する網膜色索上皮への光酸化損傷を低減、防止または改善し、そして緑内障の線維柱帯切除術および角膜再成形のための角膜切除術を含む眼のレーザー手術の間の刺激および炎症の改善のための方法も提供される。本方法は、眼科学的に許容できるキャリヤもしくは希釈剤および1種もしくはそれ以上の上記の眼科学的状態の進行を防止、遅延または症状を軽減するために治療的に十分な量のヒドロキシルアミン化合物を含んでなる組成物の投与を含んでなる。
2−エチル−2,4,4−トリメチルオキサゾリジン−3−イルオキシの還元形態である)である。本発明に使用するために適するその他のヒドロキシルアミン化合物は、非特許文献18、19、サムニら(Samuni,et al.、2001、上記)、および特許文献2(ある種のN−ヒドロキシピペリジンエステルおよび眼科を除く多数の分野での抗酸化剤としてのそれらの使用を開示)、グプタら(Gupta,et al.)への米国特許第4,404,302号明細書(ある種のN−ヒドロキシルアミンのプラスチックス成形における光安定剤としての使用を開示)、特許文献13(酸化性ストレスから生物体の防御のための置換オキサゾリジンから誘導されたある種のニトロキシドを開示)、ラミーら(Ramey,et al.)への米国特許第3,936,456号明細書(ポリマーの安定化のための置換ピペラジンジオンオキシルおよびヒドロキシドを開示)、ベーレンズら(Behrens,et al.)への米国特許第4,691,015号明細書(ヒンダードアミンから誘導されたヒドロキシルアミンおよびポリオレフィンの安定化のためのそれらのあるものの使用を記載)、およびシアら(Hsia,et al.)への数件の上記の米国特許中に開示されたものを含むがこれらに限定はされない。上記の化合物の大部分は眼への投与のためにこれまで知られていなかった。確かに、それらは皆、黄斑変性、網膜症、緑内障もしくはブドウ膜炎、または角膜、眼瞼もしくは結膜の障害の処置における使用には知られていなかった。
熱的損害を生じることができるレベルより相当低い網膜傷害を生じる光の能力は、光化学的網膜傷害と呼ばれている。光化学的網膜傷害の作用の機構は遊離基の光誘導生成と考えられる。光化学的網膜傷害を生成する臨床眼科学において一般的に使用される光源の能力は良く認識されている。眼科手術で使用される手術用顕微鏡が網膜光化学障害を起こす能力があることは証明されている。この観察は、光化学的網膜傷害を遮断する種々の薬剤の能力を試験するためにラビットの眼におけるモデルを作製するために利用される。検眼鏡的に見える網膜損傷は、手術用顕微鏡に2.5分間の短時間の暴露後でも検出できる。以下に記載するプロトコールは、硝子体内注入を介して与えられたテンポール−Hが、手術用顕微鏡により生成する検眼鏡的に見える光化学的網膜損傷の進行を遮断する能力を有するかどうかを決定するために利用される。
AMDおよびその他の網膜障害を防止するテンポール−Hの効力を評価するために、薬剤が網膜組織内に取込まれることを決定しなければならない。本実施例に記載のプロトコールは、ラビット内での硝子体注入の後に網膜組織内へのテンポール−Hの取込みの量および期間を確定するためにシンチレーション技術を利用する。ニュージーランドホワイトラビット(New Zealand White Rabbit)は、ラビットの大きい眼が処置投与のための好適な鋳型を提供するので、硝子体注入を含む実験に良く特性が研究されている(Hosseini et al.,2003,Laser Surg.Med.32:265−270)。さらに、ニュージーランドホワイトラビットはシンチレーション技術を介する網膜組織内への薬剤取り込みを評価する実験に広範に使用されている(Ahmed et al.,1987,J.Pharm.Sci.76:583−586)。
1.標識したテンポール−Hを用いる両側硝子体内注入(n=12)
2.プラセボ(ビヒクル)を用いる両側硝子体内注入(n=12)
それぞれ1、7、14および28日目に、それぞれの分岐群から3匹ずつで計6匹のラビットをペントバルビタールナトリウムの致死量投与で屠殺する。屠殺の直後に、両側摘出を行いそしてシンチレーション分析のために網膜組織を取り出す(液体の損失を防止するために網膜組織は摘出後に冷凍してもよい)。網膜組織を磨砕しスラリーとしそしてアルカリまたは第四級アンモニウム中に溶解する。シンチレーション読み取りは、網膜組織内に存在するテンポール−Hの量を定量するために行う。
背景:萎縮性加齢性黄斑変性(AMD)の病因論は完全には理解されていないけれども、AMDが網膜色索上皮細胞の死と共に開始し、光受容細胞の縮退、そしてその結果の視力の喪失がその後に起きることは一般に受容されている。それらの細胞の死と共にRPE中に蓄積するリポフスチンに関連する一団の証拠が増えている。例えば、黄斑の下層にあるRPE細胞内でリポフスチンレベルが最高であるのみならず、眼底自己蛍光の検出によるRPEリポフスチンの監視が、RPE萎縮の領域がこれまで蛍光が増加した部位で進行することも示した。RPEリポフェスチンとRPE細胞死との関連の検討に関する研究は、RPEリポフスチンの主要成分であるビスレチノイド(bisretinoid)蛍光団A2Eが細胞膜を攪乱しそしてRPEへの青色光損傷を媒介できることを示した。A2Eの光励起は、一重項酸素の生成およびエポキシドが生成するようにA2Eのレチノイド誘導側アームに沿って炭素−炭素二重結合への後者の付加に導く。この様式で、A2Eは、種々の数のエポキシドを有する化合物(A2Eエポキシド)の混合物に転換される。それらの高度に反応性のエポキシドが細胞を損傷することが示された。最終的に、RPE細胞内のA2Eの照射により誘発される光化学的事象は、細胞基質を切断するようなシステイン依存性プロテアーゼ(カスパーゼ)の関与を含みそしてミトコンドリアタンパク質bc1−2により調節される経路を介して細胞死を開始する。
Claims (13)
- 患者の眼の疾患または障害の進行を改善、遅延もしくは防止、または症状を軽減するための医薬組成物であって、該疾患または障害が光化学的網膜損傷または萎縮性加齢性黄斑変性であり、該組成物が、眼科学的に許容できるキャリヤもしくは希釈剤およびテンポール−Hを含んでなる組成物。
- テンポール−Hが0.1μM〜10mMの濃度で含まれる、請求項1の医薬組成物。
- テンポール−Hが1μM〜5mMの濃度で含まれる、請求項1の医薬組成物。
- テンポール−Hが25μM〜1mMの濃度で含まれる、請求項1の医薬組成物。
- テンポール−Hが50μM〜100μMの濃度で含まれる、請求項1の医薬組成物。
- 還元剤をさらに含んでなる、請求項1の医薬組成物。
- 該還元剤がスルフヒドリル化合物である、請求項6の医薬組成物。
- 該還元剤がメルカプトプロピオニルグリシン、N−アセチルシステイン、β−メルカプトエチルアミンまたはグルタチオンである。請求項6の医薬組成物。
- 該組成物が注入投与形態である、請求項1の医薬組成物。
- 該組成物が、点眼薬、洗眼薬または眼用軟膏剤である、請求項1の医薬組成物。
- テンポール−Hが10μM〜2.5mMの濃度で含まれる、請求項1の医薬組成物。
- テンポール−Hが50μM〜1mMの濃度で含まれる、請求項1の医薬組成物。
- テンポール−Hが100μM〜1mMの濃度で含まれる、請求項1の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52380203P | 2003-11-20 | 2003-11-20 | |
US60/523,802 | 2003-11-20 | ||
PCT/US2004/039719 WO2005051328A2 (en) | 2003-11-20 | 2004-11-22 | Amelioration of macular degeneration and other ophthalmic diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007512352A JP2007512352A (ja) | 2007-05-17 |
JP4975440B2 true JP4975440B2 (ja) | 2012-07-11 |
Family
ID=34632826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006541460A Expired - Fee Related JP4975440B2 (ja) | 2003-11-20 | 2004-11-22 | 黄斑変性およびその他の眼科疾患の改善 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20050130906A1 (ja) |
EP (2) | EP1689397A4 (ja) |
JP (1) | JP4975440B2 (ja) |
KR (1) | KR20060109947A (ja) |
CN (1) | CN100558360C (ja) |
AU (1) | AU2004293105B2 (ja) |
CA (1) | CA2546042A1 (ja) |
IL (1) | IL175380A0 (ja) |
WO (1) | WO2005051328A2 (ja) |
ZA (1) | ZA200604403B (ja) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7589107B2 (en) | 2003-05-19 | 2009-09-15 | Othera Holding, Inc. | Amelioration of vitrectomy-induced cataracts |
US20080312283A1 (en) * | 2005-05-26 | 2008-12-18 | Othera Pharmaceuticals, Inc. | Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts |
EP1888548B1 (en) | 2005-05-26 | 2012-08-22 | Neuron Systems, Inc | Quinoline derivative for the treatment of retinal diseases |
EP1904151A4 (en) * | 2005-06-22 | 2011-06-22 | Univ Pittsburgh | EMERGENCY RESERVE AND PRESERVATION METHODS |
US20070197599A1 (en) * | 2006-02-02 | 2007-08-23 | Matier William L | Hydroxylamines and derivatives as anti-angiogenic agents |
US20070197593A1 (en) * | 2006-02-22 | 2007-08-23 | Matier William L | Hydroxylamines and derivatives for treatment of inflammatory conditions of the liver |
US20070203190A1 (en) * | 2006-02-22 | 2007-08-30 | Ghanshyam Patil | Hydroxylamines and derivatives for the inhibition of complement activation |
WO2007100623A2 (en) * | 2006-02-22 | 2007-09-07 | Othera Holding, Inc. | Hydroxylamines and derivatives for the inhibition of complement activation |
US20080171072A1 (en) * | 2006-08-11 | 2008-07-17 | Frank Burczynski | Ocular inserts containing apomorphine |
EP2120942A2 (en) * | 2007-02-16 | 2009-11-25 | Othera Holding, Inc. | Drug resistance reversal in neoplastic disease |
CN101687786B (zh) * | 2007-02-22 | 2013-05-22 | 奥特拉控股公司 | 羟胺化合物及其用法 |
GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
US20100197702A1 (en) * | 2009-02-04 | 2010-08-05 | Hellberg Mark R | Ophthalmic composition with nitric oxide donor compound and method of forming and using same |
WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US9814701B2 (en) | 2009-12-11 | 2017-11-14 | Aldeyra Therapeutics, Inc. | Compositions and methods for the treatment of macular degeneration |
KR101214364B1 (ko) * | 2011-02-15 | 2012-12-21 | 한림대학교 산학협력단 | 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물 |
UA109359C2 (xx) * | 2011-11-10 | 2015-08-10 | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
RU2015120478A (ru) | 2012-12-20 | 2017-01-25 | Альдейра Терапьютикс, Инк. | Пери-карбинолы |
US9687481B2 (en) * | 2013-01-23 | 2017-06-27 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
AU2014209585A1 (en) | 2013-01-25 | 2015-07-23 | Aldeyra Therapeutics, Inc. | Novel traps in the treatment of macular degeneration |
JP6509244B2 (ja) * | 2014-10-31 | 2019-05-08 | 株式会社坪田ラボ | 水晶体硬化抑制剤 |
AU2016311158A1 (en) | 2015-08-21 | 2018-04-05 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
US10426790B2 (en) | 2016-02-28 | 2019-10-01 | Aldeyra Therapeutics, Inc. | Treatment of allergic eye conditions with cyclodextrins |
MX2018013472A (es) | 2016-05-09 | 2019-02-28 | Aldeyra Therapeutics Inc | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. |
EP3596040B1 (en) | 2017-03-16 | 2023-10-11 | Aldeyra Therapeutics, Inc. | Polymorphic salt of 6-chloro-3-amino-2(2-hydroxypropyl)quinoline and uses thereof |
AU2018348174A1 (en) | 2017-10-10 | 2020-04-23 | Aldeyra Therapeutics, Inc. | Treatment of inflammatory disorders |
CA3145888A1 (en) * | 2018-07-31 | 2020-02-06 | Isilay KAVADARLI | Ophthalmic formulations and uses thereof |
CN112714762A (zh) | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
WO2020068986A1 (en) | 2018-09-25 | 2020-04-02 | Aldeyra Therapeutics, Inc. | Formulations for treatment of dry eye disease |
JP2022526917A (ja) | 2019-03-26 | 2022-05-27 | アルデイラ セラピューティクス, インコーポレイテッド | 眼科用製剤およびその使用 |
EP3962894A4 (en) | 2019-05-02 | 2023-01-11 | Aldeyra Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND USES THEREOF |
US20210196652A1 (en) * | 2019-12-27 | 2021-07-01 | Meshaberase, LLC | Use of cysteamine and derivatives thereof to treat dysfunctional tear syndrome (dts) |
WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3936456A (en) | 1972-03-24 | 1976-02-03 | Ciby-Geigy Corporation | Substituted piperazine dione oxyls and hydroxides and polymer compositions stabilized thereby |
US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
US4300557A (en) | 1980-01-07 | 1981-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating intraocular malignancies |
US4404302A (en) | 1982-05-27 | 1983-09-13 | Ferro Corporation | Acylated hindered hexahydropyrimidines and their use as light stabilizing agents |
US4691015A (en) * | 1984-07-23 | 1987-09-01 | Ciba-Geigy Corporation | Hydroxylamines derived from hindered amines |
US5352442A (en) * | 1985-07-18 | 1994-10-04 | Proctor Peter H | Topical tempo |
FR2608045B1 (fr) * | 1986-12-12 | 1990-03-02 | Chauvin Laboratoires | Utilisation d'inhibiteurs de xanthine- oxydase, de piegeurs de radicaux libres oxygenes et de chelateurs du fer pour la fabrication d'une composition pharmaceutique destinee au traitement du glaucome et compositions pharmaceutiques destinees au traitement du glaucome |
AU1107888A (en) * | 1986-12-29 | 1988-07-27 | Pharmacia Ab | Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage |
US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
ATE249829T1 (de) * | 1990-03-16 | 2003-10-15 | Us Secretary United States Dep | Verwendung von nitroxiden und oxazolidinen zum schutz ionisierender strahlung und oxidativem stress |
US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5707643A (en) | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
US5807831A (en) * | 1993-08-16 | 1998-09-15 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5840701A (en) | 1993-08-16 | 1998-11-24 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5725839A (en) | 1993-08-16 | 1998-03-10 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI |
TW381022B (en) | 1993-08-16 | 2000-02-01 | Hsia Jen Chang | Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute |
US5817632A (en) * | 1993-08-16 | 1998-10-06 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US6458758B1 (en) | 1993-08-16 | 2002-10-01 | Synzyme Technologies, Inc. | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5824781A (en) | 1993-08-16 | 1998-10-20 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5741893A (en) | 1993-08-16 | 1998-04-21 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5767089A (en) | 1993-08-16 | 1998-06-16 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5804561A (en) | 1993-08-16 | 1998-09-08 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5773021A (en) | 1994-03-14 | 1998-06-30 | Vetoquinol S.A. | Bioadhesive ophthalmic insert |
US5466233A (en) * | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
US5527533A (en) * | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
EP0792266B1 (en) | 1994-11-15 | 2000-07-12 | Moreno Paolini | N-hydroxypiperidines as superoxide radicals scavengers |
US5725493A (en) * | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US5718922A (en) | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
US6469057B1 (en) * | 1995-06-02 | 2002-10-22 | Mcw Research Foundation, Inc. | Methods for in vivo reduction of free radical levels and compositions useful therefor |
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
WO1997026879A1 (en) * | 1996-01-26 | 1997-07-31 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health | Hydroxylamine compositions for the prevention or retardation of cataracts |
US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
FR2773320B1 (fr) * | 1998-01-05 | 2000-03-03 | Optisinvest | Dispositif pour le transfert intraoculaire de produits actifs par iontophorese |
JP2002506022A (ja) * | 1998-03-13 | 2002-02-26 | センター ファーマシューティカルズ, インコーポレイテッド | 新脈管形成の阻害 |
US6410045B1 (en) * | 1999-02-22 | 2002-06-25 | Clyde Lewis Schultz | Drug delivery system for antiglaucomatous medication |
CA2378257A1 (en) * | 1999-08-10 | 2001-02-15 | William E. Sponsel | Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight |
US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6375972B1 (en) * | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
AU2001293064A1 (en) * | 2000-09-26 | 2002-04-08 | Georgetown University | Use of nitroxides for the treatment of vascular disorders in a diabetic mammal |
US6713081B2 (en) | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
CA2484512C (en) * | 2002-05-17 | 2013-04-16 | Othera Pharmaceuticals, Inc. | Treatment of cataracts and other ophthalmic diseases |
AU2003300471A1 (en) * | 2003-01-03 | 2004-08-10 | Eric F. Bernstein | Methods for treating ocular diseases |
GB2405793A (en) * | 2003-09-12 | 2005-03-16 | 4 Aza Bioscience Nv | Pteridine derivatives for treating TNF-alpha related disorders |
-
2004
- 2004-11-22 US US10/994,724 patent/US20050130906A1/en not_active Abandoned
- 2004-11-22 EP EP04812278A patent/EP1689397A4/en not_active Withdrawn
- 2004-11-22 AU AU2004293105A patent/AU2004293105B2/en not_active Ceased
- 2004-11-22 WO PCT/US2004/039719 patent/WO2005051328A2/en active Application Filing
- 2004-11-22 ZA ZA200604403A patent/ZA200604403B/en unknown
- 2004-11-22 CA CA002546042A patent/CA2546042A1/en not_active Abandoned
- 2004-11-22 KR KR1020067012106A patent/KR20060109947A/ko not_active Application Discontinuation
- 2004-11-22 JP JP2006541460A patent/JP4975440B2/ja not_active Expired - Fee Related
- 2004-11-22 CN CNB2004800343561A patent/CN100558360C/zh not_active Expired - Fee Related
- 2004-11-22 EP EP09150175A patent/EP2052720A3/en not_active Withdrawn
-
2006
- 2006-05-02 IL IL175380A patent/IL175380A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2004293105B2 (en) | 2010-09-09 |
WO2005051328A2 (en) | 2005-06-09 |
EP2052720A2 (en) | 2009-04-29 |
KR20060109947A (ko) | 2006-10-23 |
CN1882339A (zh) | 2006-12-20 |
WO2005051328A3 (en) | 2005-06-30 |
IL175380A0 (en) | 2008-04-13 |
US20050130906A1 (en) | 2005-06-16 |
EP2052720A3 (en) | 2009-05-06 |
CA2546042A1 (en) | 2005-06-09 |
ZA200604403B (en) | 2007-09-26 |
JP2007512352A (ja) | 2007-05-17 |
CN100558360C (zh) | 2009-11-11 |
AU2004293105A1 (en) | 2005-06-09 |
EP1689397A4 (en) | 2007-06-20 |
EP1689397A2 (en) | 2006-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4975440B2 (ja) | 黄斑変性およびその他の眼科疾患の改善 | |
Brown et al. | ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery | |
US10688092B2 (en) | Compositions and methods of using nintedanib for improving glaucoma surgery success | |
Casson | Medical therapy for glaucoma: A review | |
US8414911B2 (en) | Photochemical therapy to affect mechanical and/or chemical properties of body tissue | |
JP5696121B2 (ja) | α−2アドレナリン受容体アゴニスト含有生分解性眼内インプラント | |
JP2020147606A (ja) | 安定で保存剤非含有の散瞳および抗炎症注射用液剤 | |
Prabhasawat et al. | Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium | |
WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
US11045352B2 (en) | Methods for treatment of dry eye and other acute or chronic inflammatory processes | |
KR20100072333A (ko) | 약물 전달을 위한 비히클로서의 비-수성 수혼화성 물질 | |
CA2429982C (en) | Copper chelators for treating ocular inflammation | |
KR20070040326A (ko) | 백내장, 황반 변성 및 다른 안과 질환의 개선 | |
US7825134B2 (en) | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | |
US7589107B2 (en) | Amelioration of vitrectomy-induced cataracts | |
Scherrer et al. | Corneal edema in four horses treated with a superficial keratectomy and Gundersen inlay flap | |
Sakamoto et al. | Electroporation and bleomycin in glaucoma-filtering surgery. | |
AU2004255199A1 (en) | Coumarin derivatives for the treatment of ophthalmic disorders | |
RU2434633C2 (ru) | Фармацевтические препаративные формы латрункулина | |
Bertens et al. | Combination drug delivery approaches in ophthalmology | |
US20080312283A1 (en) | Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts | |
Sharma et al. | Novel Perspectives in Treatment of Fungal Keratitis | |
SUTPHIN | Corneal Crosslinking with Riboflavin and Ultraviolet A. Part II. Clinical Indications and Results |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071120 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20081023 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110308 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110607 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110614 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110707 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110714 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110805 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110812 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110907 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120313 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120411 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150420 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150420 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |